- Short Report
- Open Access
Ribozyme-mediated gene knock down strategy to dissect the consequences of PDGF stimulation in vascular smooth muscle cells
© Lande et al.; licensee BioMed Central Ltd. 2012
- Received: 19 February 2012
- Accepted: 7 June 2012
- Published: 10 July 2012
Vascular Smooth Muscle Cells (VSMCs), due to their plasticity and ability to shift from a physiological contractile-quiescent phenotype to a pathological proliferating-activated status, play a central role in the onset and progression of atherosclerosis and cardiovascular diseases. PDGF-BB, among a series of cytokines and growth factors, has been identified as the critical factor in this phenotypic switch. In order to obtain new insights on the molecular effects triggered by PDGF-BB, a hammerhead ribozyme targeting the membrane receptor PDGFR-β was applied to inhibit PDGF pathway in porcine VSMCs.
Ribozymes, loaded on a cationic polymer-based vehicle, were delivered into cultured VSMCs. A significant impairment of the activation mechanisms triggered by PDGF-BB was demonstrated since cell migration decreased after treatments. In order to functionally validate the effects of PDGFR-β partial knock down we focused on the phosphorylation status of two proteins, protein disulfide isomerase-A3 (PDI-A3) and heat shock protein-60 (HSP-60), previously identified as indicative of VSMC phenotypic switch after PDGF-BB stimulation. Interestingly, while PDI-A3 phosphorylation was counteracted by the ribozyme administration indicating that PDI-A3 is a factor downstream the receptor signalling cascade, the HSP-60 phosphorylation status was greatly increased by the ribozyme administration.
These contradictory observations suggested that PDGF-BB might trigger different parallel pathways that could be modulated by alternative isoforms of the receptors for the growth factor. In conclusion the knock down strategy here described enables to discriminate between two tightly intermingled pathways. Moreover it opens new attractive perspectives in functional investigations where combined gene knock down and proteomic technologies would allow the identification of key factors and pathways involved in VSMC-linked pathological disorders.
- Hammerhead ribozyme
- Vascular smooth muscle cells
- Cardiovascular disease
- Functional proteomics
Coronary artery disease (CAD) is a pathological status induced by the reduction or block of the bloody flow caused by atherosclerotic plaques narrowing or obstructing the arterial lumen. It is well-known that VSMCs play a central role in the onset and progression of the disease and also in the complications observed after Percutaneous Transluminal Coronary Angioplasty (PTCA) that represents the most frequent clinical approach to CAD. Indeed, VSMCs may change their quiescent-contractile physiological phenotype, once subjected to external stimuli, such as cytokines and growth factors, and acquire an activated state endowed with proliferative and migratory properties.
Among the activating growth factors, PDGF-BB, produced by activated platelets and macrophages, has so far been the only factor demonstrated to selectively and directly promote the VSMC phenotype switch [1, 2]. The role of PDGF receptors has been described in post injury models  and it was detected in human coronary arteries following balloon angioplasty . As a consequence of their induced activation, VSMCs migrate to the sub-intimal space, proliferate, and secrete abundant amounts of extracellular matrix, which forms the bulk of the intimal hyperplastic lesion contributing to restenosis .
A series of conventional cytostatic drugs has been adopted to prevent VSMC proliferation and migration after PTCA but a consistent percentage of side effects has been described . More selective nucleic acid-based drugs have been proposed and experimented . Among these drugs, the most frequently exploited ones are ribozymes and siRNAs. Both these inhibitors are interesting since they may be tailored to target and inhibit selectively the genes of interest. The last decade has been characterized by an extraordinary siRNA uptrend, due to the low cost and easy availability. Nevertheless, siRNAs display some disadvantages, since they may saturate cellular machineries and induce off-target effects . Conversely, ribozymes, although more complicated and time consuming in the design, synthesis and validation, are self-acting and more specific.
Hammerhead trans-acting ribozymes are the smallest RNA molecules capable of endonucleolytic activity that specifically bind and cleave RNA sequences of definite targets. Impressively, these precise molecular tools are able to discriminate between targets differing by a single nucleotide  and this is the main reason why they have been repeatedly proposed as therapeutic agents also in the field of cardiovascular diseases . In the last years, a different application of ribozymes has stood out with the impressive development of proteomics technologies.
This paper describes the design and experimentation of a hammerhead ribozyme-mediated gene knock down strategy able to dissect PDGF-BB signaling pathway in order to evidence how a single receptor can activate alternative signaling cascades thus emerging as important switch in VSMC phenotype modulation.
Oligonucleotides sequences, synthesis and purification
Selection of target sequence within the porcine PDGFR-β [sequence accession number AF347050S1] and of related minimal ribozyme has been performed according to our previously described predictive method . Selected sequences were: active hammerhead ribozyme, 5′ UCC UUG CUG AUG AGG CCG AAA GGC CGA AAC CAU AU 3′, inactive hammerhead ribozyme, 5′ UCC UUG CUA AUG AGG CCG AAA GGC CGA AAC CAU AU 3′ (in bold the inactivating mutation) and short mRNA substrate, 5′ GUC AUA UGG UUC AAG GAC AAC 3′, containing the cleavage target triplet GUU mimicking the position 288–290 of the mRNA. Syntheses have been performed by phosphoramidite chemistry in an AB 3400 synthesizer (Applied Biosystems) using a home-adapted coupling protocol. Crude oligonucleotides were de-protected by treatment with 2 mL of a 1:3 (v/v) mixture of ethanol and 33% ammonium hydroxide (Sigma Aldrich) at 55°C for 12 h and then concentrated to dryness. Crude products were desalted by gel-filtration chromatography in a Sephadex G25 column run in sterile water. Oligonucleotides were then purified by semi-preparative anion-exchange HPLC chromatography on 1.6x10 cm Source® 15Q column (GE Healthcare) eluted at 6 mL/min with 30 min linear gradient from 0.25 to 0.75 M NaCl in 20 mM Tris–HCl buffer pH 9.0 supplemented with 10% acetonitrile (v/v). A recovered fraction, was desalted, as before, by Sephadex G25 gel-filtration chromatography. The freeze-dried collected products were treated with 1:3 (v/v) solution of N,N-dimethylformamide and triethylamine trihydrofluoride (Sigma Aldrich) to remove the 2′O tetrabutyldimethylsilylic protective group. Free products, desalted once again by gel-filtration, were UV quantified at 260 nm absorption measurements in a UV–VIS spectrophotometer (FluoSTAR) before use. A dye-labeled 25mer DNA oligonucleotide (OligoF) was also synthesized.
In vitro measurement of kinetic constants
A multiple turnover kinetic assay was performed in standard conditions (37°C, pH 7.4, [Mg+2] = 10 mM) using a constant 0.2 μM ribozyme concentration and variable amounts of substrate in order to obtain ratios of ribozyme to substrate of 1:10, 1:40, 1:120, 1:180. Stock Ribozyme substrate solutions were separately prepared in a reaction buffer containing 10 mM MgCl2, and then heated at 95°C for 2 minutes to denature any secondary structure of RNA molecules. Cleavage reactions were started by adding a constant amount of ribozyme to the substrate solutions at 37°C. At fixed time point (1′, 2′, 3′, 6′, 9′, 12′, 15′, 20′) aliquots were drawn from the reaction mixture and the reaction stopped by adding 50 mM EDTA to abolish the Mg+2 contribute to ribozyme activity. Recovered fractions were then analyzed by ion-exchange liquid chromatography using a 4 × 250 mm DNA-Pak® PA-200 column (DIONEX). Runs were performed in a “200 series” apparatus (Perkin Elmer) at 50°C with a flow rate of 1 mL/min under a 30 min linear gradient from 100 to 340 mM sodium perchlorate (Sigma-Aldrich) in 20 mM Tris–HCl buffer pH 9.5 supplemented with 10% acetonitrile. UV signals (recorded at 260 nm) enabled us to quantify the full-length substrate and cleavage products.
Synthesis of the vehicle A41-PEI
A two-step synthesis was performed according to our previous experience . Firstly, 6.5 nmol of Polyethylenimine (PEI) (MW 25 KDa Sigma-Aldrich) in PBS buffer pH 7.2, were reacted at 37°C for 3 h with 650 nmol of the bifunctional succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC) crosslinker dissolved in DMSO. Unreacted SMCC was removed by 10000 molecular weight cut-off centrifugation at 10000 rpm for 20 min at 18°C (Microcon YM10, Millipore). The maleimide-activated PEI was then reacted overnight at room temperature with 650 nmol of the cystein modified third helix homeodomain fragment of the Drosophila Melanogaster antennapedia transcription factor (A41): C RQIKIWFQNRRMKWKK (Espikem, Italy). Final purification was obtained by further 45 min cut-off centrifugation at 10000 rpm , at 18°C, using the same centrifugal filter as before in order to discard any unreacted A41. The purified A41-PEI vehicle was quantified by absorption measurement at 280 nm (CARY 100, Varian).
VSMC isolation and cultures
Coronaries were dissected from the myocardium of 8-month-old domestic pigs (Sus scrofa domestica) obtained from a local slaughterhouse (operating under the local institutional legislation according to ethical directives). VSMCs from tunica media were isolated by enzymatic digestion according to the method described by Christen et al.  and cultured in DMEM HG (GIBCO) medium containing 10% FBS (Fetalclone). All reported experiments were performed using cells between the second and sixth passage.
Oligonucleotide transfections into VSMCs
The oligonucleotide delivery to cells was performed using the described A41-PEI vehicle. The oligonucleotide amount to be charged onto vehicle, tested under variable N/P ratio (theoretical amine to phosphate groups ratio), was optimized by using the fluorescent OligoF. VSMCs were seeded in 12-well plates at a density of 100,000 cells/well for transfection experiments. After 24 hr, fresh medium, supplemented with 10% FBS and containing oligonucleotide-loaded vehicle, corresponding to 250 nM of ribozyme or OligoF, was added to the wells. 24 hr later, the cells were, washed in PBS and then either cultured for biological assays or fixed for immunofluorescence.
Immunofluorescence analyses were carried out on cells grown and transfected on coverslips. The cells were fixed at 4°C for 30 min with 2% paraformaldehyde in PBS and the fluorescence images were recorded using a DMLB microscope (Leica Microsystems).
Quantitative real-time PCR
Primers designed to produce a 137 bp amplification product from PDGFR-β mRNA encompassing the cleavage site of hammerhead ribozyme were: forward primer 5′ GACGCCGTGCAA 3′ and reverse primer 5′GACAGCGCGATCTC 3′. Similar size product from β-actin housekeeping reference transcript was designed and relative primers were: forward 5′CCAACCGCGAGAAGATGA 3′ and reverse CCAGAGGCGTACAGGGATAG 3′. Crude RNA was extracted from control (untreated) or 24 hr ribozyme-treated VSMCs using RNAeasy extraction kit (Qiagen). Aliquots containing 1 μg of total RNA were retrotranscribed using QuantiTect reverse transcription kit (Qiagen) according to manufacturer’s instructions. Quantitative real-Time PCR (qRT-PCR) was carried out with LightCycler 480 (Roche Applied Science). Reactions were performed using LightCycler 480 SYBR Green I Master kit (Roche) under standard conditions. Relative quantification of mRNA was calculated with standard curve method. Transcript values were normalized with those obtained for β-actin (internal control). Each point represents the mean ± SE of at least three independent experiments.
For the determination of cell viability, VSMCs were seeded in 96-well culture plates at a density of 1000 cells in 100 μL of complete medium per well. 24 hr after seeding, cells were transfected as described above and at interval of 24 hr after transfection 20 μL of 3-(4.5-dimethylthiazole-2-yl)-2.5-diphenyl tetrazolium bromide (MTT) reagent (CellTiter 96® Cell Proliferation Assay, Promega) were added to each well. Following 2 hr of incubation at 37°C to allow color development, absorbance was recorded using a 96-well plate reader (Fluostar Omega, BMG Labtech). Viability tests were carried out on untreated as well as treated VSMC cultures using three concentrations (115 nM, 220 nM, 330 nM) of both active and inactive ribozymes. All measurements were performed in triplicate.
VSMCs were plated and transfected with 250 nM of active or inactive ribozymes in 12-well plates, as described above. 24 hr after transfection, a straight scratch, simulating a wound, was made on the cell layer using a pipette tip. Thereafter, 10 ng PDGF-BB were added to the wells for every ml of culture medium. 24 hr later, the cells were fixed with formalin and stained with crystal violet. A dedicated image analysis program (Optiquant, Packard Instruments) allowed the quantification of cells that had migrated into the scratch.
Chemotaxis was measured using the Cultrex® Cell Migration Assay (Trevigen Inc.) according to the manufacturer’s instructions. Briefly, this assay utilizes a simplified boyden chamber design with an 8 micron polyethylene terephthalate (PET) membrane. PDGF-BB (10 ng/mL) was used as chemoattractant. Detection of cell migration was quantified using Calcein AM (acetomethylester). Calcein AM is internalized by the cells and intracellular esterases cleave the AM. Free Calcein fluoresces brightly and the fluorescence is used to quantitate the number of cells that have migrated using a standard curve. 50 000 cells were seeded in each well. Plate was read with a Microplate Luminometer (Glomax Multi Detection System – Promega) using a 485 nm excitation and 520 nm emission conditions.
2D-PAGE, mass spectrometry and western blot
Crude proteins were extracted as described by Rocchiccioli et al  from VSMCs, treated or not with oligonucleotide inhibitors, stimulated for 10 min with PDGF-BB. Protein content was quantified by standard bicinchoninic acid (BCA) assay. Proteins were separated by isoelectrofocusing (IEF) according to the method originally described in Görg et al.  using pre-manufactured strips with an immobilized non-linear pH gradient ranging from 3 to 10 (Amersham Biosciences, Uppsala, Sweden) on a Ettan IPGphor system (Amersham Biosciences). Second dimension was run on a 9-16% sodium dodecyl sulfate - polyacrylamide gel gradient (SDS- PAGE). Gels were stained in ammoniacal silver nitrate according to the method described in Hochstrasser et al. . The analysis of digital images was carried out with Image Master computer software (GeneBio, Geneva, Switzerland) and only those spots with over 3-fold changes in volume after normalization between the different samples were defined as altered.
Electrophoretic spots were excised and proteins were in-gel digested by trypsin. Peptides were analysed by mass spectrometry (4800 MALDI TOF/TOF - Applied Biosystems).Identification of the proteins was carried out using MASCOT search engine version 2.1 (Matrix Science, Boston, MA).
For immunodetection of Tyrosine-phosphoproteins, after separation by 2D-PAGE, proteins were transferred onto nitrocellulose membranes (Hybond-C, Amersham Life Science). Membranes were incubated overnight at 4°C with a mouse anti-phosphotyrosine monoclonal antibody (IgG2b; Santa Cruz Biotechnology) diluted 1:1,000 in 3% BSA, 0.1% Tween-20 in PBS and then with the secondary antibody, HRP-conjugated anti-mouse IgG (Santa Cruz Biotechnology), diluted 1:3,000, for 1 h at room temperature. Chemiluminescence was detected by an ECL™ Detection Kit (Amersham Biosciences) following the manufacturer’s protocol.
Data were statistically elaborated using the unpaired t-test (* P < 0.05, ** P < 0.01, ***P < 0.001). Each result refers to three independent experiments.
Results and discussion
Kinetic characterization and transfection of hammerhead ribozymes
The kcat value of 12.8 min-1 is indicative of a high rate of the cleavage step, usually ranging from 1 to 10 min-1 for synthetic minimal hammerhead ribozymes. The catalytic efficiency, i.e. the turnover number kcat/KM, was 0.31 106 min-1 M-1, a value comparable with those described for other biologically active ribozymes [18, 19].
A polymer-based vehicle was designed according to our previous experience . Polyethyleneimine (PEI 25 k) instead of poly-L-lysine was adopted due to its lower toxicity and higher activity as transfecting agent . Moreover, PEI is a commercially available, universally accepted vehicle and can be considered the golden standard among the non-viral transfecting agents. As cell penetrating peptide (CPP) we adopted the third helix homeodomain fragment (A41) of the Drosophila Melanogaster antennapedia transcription factor since it is a characterized by a high efficiency to cross the cell membranes [21, 22]. The number of A41 molecules bound to primary amino-groups of PEI ranged around a ratio of 1 to 10 which was previously observed to represent an optimized compromise between delivery effectiveness and toxicity. The ultrafiltration-coupled preparation method of vehicle enabled to obtain a 60% yield from starting reagents.
Transfection efficiency of vehicle was monitored under different N/P ratios (amine group of PEI over phosphate groups of oligonucleotides) exploiting OligoF and evaluating the content of incorporated fluorescence into cultured cells by cytofluorimetry. Even under lower N/P conditions (N/P = 6), 48% of cells became fluorescent due to the intake of OligoF. A saturation of delivery activity (over the 90% of cells) was reached for N/P higher than 17. Such results demonstrate the active synergistic effect of membrane-fusogenic A41 peptide which improves the ability of the complex “vehicle/oligonucleotide” to cross the cell membrane.
The uptake of the oligonucleotide into the cells was also checked at morphological level by fluorescence light microscopy analyses. Perinuclear fluorescence was evident in 90% of the cells and appeared to be clustered into small roundish vesicles (Figure 1B).
PDGFR-β knock down assessment and toxicity of the treatments
Viability tests after treatments with three different amount of active or inactive ribozymes have been performed up to 5 days. Cells were cultured in the presence of the ribozyme bound to the A41-PEI vehicle at constant N/P ratio of 17. Records of the formazan product by absorbance at 490 nm was measured at 24 h intervals (Figure 2B). No substantial differences can be observed either between active and inactive ribozymes also among the different doses used. The slight delay in the curves, observed in all oligonucleotide-treated cultures as compared to controls, might reflect the overall cell perturbation provided by the polyplexed complex (vehicle + oligonucleotide).
Effects of PDGFR-β gene knock down on VSMC migration
Chemotaxis (Figure 3B) was also analysed in Boyden chambers using PDGF-BB as chemoactrator. The number of migrating cells was significantly reduced of about 32% by the ribozyme administration as compared to untreated or inactive ribozyme treated cultures.
Knock down-induced changes on protein phosphorylation
This study was triggered by a previous published work  in which PDGF-BB resulted to heavily affect the phosphoproteome profile of VSMCs. Among other factors, heat-shock proteins and other chaperones have been indicated to participate actively to cell remodeling after growth factor stimulation and to contribute to the so called “inside-out” cross talk, responsible of the cell activation . In particular, HSP-60 and PDI-A3 seemed interesting for the assessment of our partial knock down system since HSP-60 has been well demonstrated as being involved in cardiovascular diseases [25, 26] with a suggested role in VSMC migration [26, 27]. Accumulating evidence has revealed the presence of chaperones (HSP-60 and PDI-A3) on cell surface and it has also proposed that their tyrosine phosphorylation might constitute a possible mechanism for reorientation of receptor complexes and key molecules in the process of cell activation [28–30]. This mechanism is particular interesting in the VSMC phenotypic switch that characterizes their activation and entails important changes in membrane morphology and composition. Major outcome of this phenomenon is the acquisition of a migratory capability. In this respect, it has been reported that PDI-A3 functions at the cell surface, where it may be involved in disulfide exchange required for cell mediated adhesion by integrins . Interestingly, it has also been shown that PDI-A3 can mediate conformational changes in both β1 and β3 integrins, which may lead to cell adhesion to a particular substrate . Moreover, PDI-A3 might be committed with PDGF targeting to its receptors . For all this reasons, PDI-A3 and HSP-60 chaperones were selected in order to validate our knock-down results.
With the administration of hammerhead ribozymes, a significant reduction of the PDGFR-β target mRNA was obtained. This treatment appeared devoid of any toxic side effects and considerably affected the PDGF-BB signaling activity as revealed by biological assays. Indeed, migration activity in ribozyme-treated cultures, monitored by wound assay, fell down to 10% of levels attributed to PDGF stimulated cells. The specificity of such a knocking down effect was confirmed by the very small inhibition induced by similar administration of the inactive ribozyme.
The model described in this figure, once confirmed, would open new attractive perspectives in studies of functional proteomics. Combined proteomic and gene knock down technologies would enable the identification of key factors and key pathways involved in VSMC activation and eventually suggest crucial elements suitable for diagnostic evaluations and useful for planning new therapeutic strategies.
This study was partially supported by grant from FP7-ICT-2007 project ARTreat (grant agreement 224297).
- Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004, 84: 767-801. 10.1152/physrev.00041.2003.PubMedView ArticleGoogle Scholar
- Gerthoffer WT: Mechanisms of vascular smooth muscle cell migration. Circ Res. 2007, 100: 607-621. 10.1161/01.RES.0000258492.96097.47.PubMedView ArticleGoogle Scholar
- Davies MG, Owens EL, Mason DP, Lea H, Tran PK, Vergel S, Hawkins SA, Hart CE, Clowes AW: Effect of platelet-derived growth factor receptor-alpha and -beta blockade on flow-induced neointimal formation in endothelialized baboon vascular grafts. Circ Res. 2000, 86: 779-786. 10.1161/01.RES.86.7.779.PubMedView ArticleGoogle Scholar
- Tanizawa S, Ueda M, vanderLoos CM, vanderWal AC, Becker AE: Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: An immunohistochemical study. Heart. 1996, 75: 549-556. 10.1136/hrt.75.6.549.PubMedPubMed CentralView ArticleGoogle Scholar
- Cecchettini A, Rocchiccioli S, Boccardi C, Citti L: Vascular smooth muscle-cell activation: proteomics point of view. Int Rev Cell Mol Biol. 2011, 288: 43-99.PubMedView ArticleGoogle Scholar
- Lowe HC, Schwartz RS, Mac Neill BD, Jang LK, Hayase M, Rogers C, Oesterle SN: The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents. Catheter Cardiovasc Interv. 2003, 60: 515-523. 10.1002/ccd.10705.PubMedView ArticleGoogle Scholar
- Bhindi R, Fahmy RG, Lowe HC: Brothers in arms - DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. American J Pathology. 2007, 171: 1079-1088. 10.2353/ajpath.2007.070120.View ArticleGoogle Scholar
- Tedeschi L, Lande C, Cecchettini A, Citti L: Hammerhead ribozymes in therapeutic target discovery and validation. Drug Discov Today. 2009, 14: 776-783. 10.1016/j.drudis.2009.05.003.PubMedView ArticleGoogle Scholar
- Phylactou LA, Tsipouras P, Kilpatrick MW: Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target. Biochem Biophys Res Commun. 1998, 249: 804-810. 10.1006/bbrc.1998.9241.PubMedView ArticleGoogle Scholar
- Citti L, Rainaldi G: Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Curr Gene Ther. 2005, 5: 11-24.PubMedView ArticleGoogle Scholar
- Mercatanti A, Rainaldi G, Mariani L, Marangoni R, Citti L: A method for prediction of accessible sites on an mRNA sequence for target selection of hammerhead ribozymes. J Comput Biol. 2002, 9: 641-653. 10.1089/106652702760277363.PubMedView ArticleGoogle Scholar
- Citti L, Rovero P, Colombo MG, Mariani L, Poliseno L, Rainaldi G: Efficacy of an amphipathic oligopeptide to shuttle and release a cis-acting DNA decoy into human cells. Biotechniques. 2002, 32: 172-+-PubMedGoogle Scholar
- Christen T, Bochaton-Piallat ML, Neuville P, Rensen S, Redard M, van Eys G, Gabbiani G: Cultured porcine coronary artery smooth muscle cells - a new model with advanced differentiation. Circ Res. 1999, 85: 99-107. 10.1161/01.RES.85.1.99.PubMedView ArticleGoogle Scholar
- Rocchiccioli S, Citti L, Boccardi C, Ucciferri C, Tedeschi L, Lande C, Trivella MG, Cecchettini A: A gel-free approach in vascular smooth muscle cell proteome: perpectives for a better insight into activation. Proteome Science. 2010, 8: 1-15. 10.1186/1477-5956-8-1.View ArticleGoogle Scholar
- Görg A, Obermaier C, Boguth G, Weiss W: Recent developments in two-dimensional gel electrophoresis with immobilized pH gradients: wide pH gradients up to pH 12, longer separation distances and simplified procedures. Electrophoresis. 1999, 20: 712-717. 10.1002/(SICI)1522-2683(19990101)20:4/5<712::AID-ELPS712>3.0.CO;2-Y.PubMedView ArticleGoogle Scholar
- Hochstrasser DF, Patchornik A, Merril CR: Development of polyacrylamide gels that improve the separation of proteins and their detection by silverstaining. Anal Biochem. 1988, 173: 412-423. 10.1016/0003-2697(88)90208-4.PubMedView ArticleGoogle Scholar
- Blalock TD, Yuan R, Lewin AS, Schultz GS: Hammerhead ribozyme targeting connective tissue growth factor mRNA blocks transforming growth factor-beta mediated cell proliferation. Exp Eye Res. 2004, 2004 (78): 1127-1136.View ArticleGoogle Scholar
- Citti L, Boldrini L, Nevischi S, Mariani L, Rainaldi G: Quantitation of in vitro activity of synthetic trans-acting ribozymes using HPLC. Biotechniques. 1997, 23: 898-903.PubMedGoogle Scholar
- Chilakamarthi U, Murherjee SK, Deb JK: Intervention of geminiviral replication in yeast by ribozyme mediated downregulation of its Rep protein. FEBS Lett. 2007, 581: 2675-2683. 10.1016/j.febslet.2007.04.084.PubMedView ArticleGoogle Scholar
- Eliyahu H, Barenholz Y, Domb AJ: Polymers for DNA delivery. Molecules. 2005, 10: 34-64. 10.3390/10010034.PubMedView ArticleGoogle Scholar
- Prochiantz A: Messenger proteins: homeoproteins, TAT and others. Curr Opin Cell Biol. 2000, 12: 400-406. 10.1016/S0955-0674(00)00108-3.PubMedView ArticleGoogle Scholar
- Morris MC, Deshayes S, Heitz F, Divita G: Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell. 2008, 100: 201-217. 10.1042/BC20070116.PubMedView ArticleGoogle Scholar
- Giannini CD, Roth WK, Piiper A, Zeuzem S: Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture. Nucleic Acids Res. 1999, 27: 2737-2744. 10.1093/nar/27.13.2737.PubMedPubMed CentralView ArticleGoogle Scholar
- Boccardi C, Cecchettini A, Caselli A, Camici G, Evangelista M, Mercatanti A, Rainaldi G, Citti L: A proteomic approach to the investigation of early events involved in the activation of vascular smooth muscle cells. Cell Tissue Res. 2007, 329: 119-128. 10.1007/s00441-007-0407-5.PubMedView ArticleGoogle Scholar
- Snoeckx L, Cornelussen RN, Van Nieuwenhoven FA, Reneman RS, Van Der Vusse GJ: Heat shock proteins and cardiovascular pathophysiology. Physiol Rev. 2001, 81: 1461-1497.PubMedGoogle Scholar
- Pockley AG, de Faire U, Kiessling R, Lemne C, Thulin T, Frostegard J: Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens. 2002, 20: 1815-1820. 10.1097/00004872-200209000-00027.PubMedView ArticleGoogle Scholar
- Barazi HO, Zhou LG, Templeton NS, Krutzsch HC, Roberts DD: Identification of heat shock protein 60 as a molecular mediator of alpha 3 beta 1 integrin activation. Cancer Res. 2002, 62: 1541-1548.PubMedGoogle Scholar
- Kelly L, Asquith RM, Baleato EA, McLaughlin BN, Aitken NJ: Tyrosine phosphorylation activates surface chaperones facilitating sperm-zona recognition. J Cell Sci. 2004, 117: 3645-3657. 10.1242/jcs.01214.View ArticleGoogle Scholar
- Turano C, Coppari S, Altieri F, Ferraro A: Proteins of the PDI family: unpredicted non-ER locations and functions. J Cell Physiol. 2002, 193: 154-163. 10.1002/jcp.10172.PubMedView ArticleGoogle Scholar
- Goplen D, Wang J, Enger PØ, Tysnes BB, Terzis AJ, Laerum OD, Bjerkvig R: Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 2006, 66: 9895-9902. 10.1158/0008-5472.CAN-05-4589.PubMedView ArticleGoogle Scholar
- Lahav J, Wijnen EM, Hess O, Hamaia SW, Griffiths D, Makris M, Knight CJ, Essex DW, Farndale RW: Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin α2β1. Blood. 2003, 102: 2085-2092. 10.1182/blood-2002-06-1646.PubMedView ArticleGoogle Scholar
- Lahav J, Gofer-Dadosh N, Luboshitz J, Hess O, Shaklai M: Protein disulfide isomerase mediates integrin dependent adhesion. FEBS Lett. 2000, 475: 89-92. 10.1016/S0014-5793(00)01630-6.PubMedView ArticleGoogle Scholar
- Hogg PJ, Hotchkiss KA, Jimenez BM, Stathakis P, Chesterman CN: Interaction of platelet-derived growth factor with thrombospondin 1. Biochem J. 1997, 326: 709-716.PubMedPubMed CentralView ArticleGoogle Scholar
- Yu J, Deuel TF, Kim H-RC: Platelet-derived Growth Factor (PDGF) Receptor-α Activates c-Jun NH2-terminal Kinase-1 and Antagonizes PDGF Receptor-β-induced Phenotypic Transformation. J Biol Chem. 2000, 275: 19076-19082. 10.1074/jbc.M910329199.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.